AstraZeneca
AZN
603 hedge funds and large institutions have $19.8B invested in AstraZeneca in 2020 Q1 according to their latest regulatory filings, with 61 funds opening new positions, 196 increasing their positions, 223 reducing their positions, and 85 closing their positions.
30% more funds holding in top 10
Funds holding in top 10: 10 → 13 (+3)
0.18% less ownership
Funds ownership: 17.03% → 16.85% (-0.18%)
2% less call options, than puts
Call options by funds: $88.9M | Put options by funds: $90.8M
5% less funds holding
Funds holding: 633 → 603 (-30)
11% less capital invested
Capital invested by funds: $22.3B → $19.8B (-$2.53B)
12% less repeat investments, than reductions
Existing positions increased: 196 | Existing positions reduced: 223
28% less first-time investments, than exits
New positions opened: 61 | Existing positions closed: 85
Top Buyers
| 1 |
Capital International Investors
Los Angeles,
California
|
+$253M |
| 2 |
Renaissance Technologies
New York
|
+$138M |
| 3 |
BlackRock
New York
|
+$104M |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
+$102M |
| 5 |
Jennison Associates
New York
|
+$101M |
Top Sellers
AZN Hedge Fund Activity: Q1 2020 in Review
603 of the 4,538 institutional investors tracked by Wall St. Rank reported a position in AstraZeneca (AZN) for Q1 2020, worth a combined $19.8B — down 11% from $22.3B a quarter earlier.
Sellers outnumbered buyers: 85 funds closed out of AZN and 61 opened new positions — a net loss of 24 holders — while 223 trimmed existing stakes and 196 added.
The largest buyer was Capital International Investors, adding an estimated $253M. The largest seller was Dodge & Cox, cutting an estimated $404M.
- 603 institutional investors held AstraZeneca (AZN) as of Q1 2020, down from 633 in Q4 2019.
- Funds reported $19.8B of AstraZeneca stock for Q1 2020, down 11% quarter-over-quarter.
- 61 funds opened new AstraZeneca positions in Q1 2020 and 85 closed out, a net change of -24 holders.
- The largest AstraZeneca buyer in Q1 2020 was Capital International Investors, an estimated $253M added.
- The largest AstraZeneca seller in Q1 2020 was Dodge & Cox, an estimated $404M sold.
Based on aggregated 13F filings for Q1 2020.